These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11721458)

  • 1. Antiarrhythmic drugs and ventricular defibrillation energy requirements.
    Qi X; Dorian P
    Chin Med J (Engl); 1999 Dec; 112(12):1147-52. PubMed ID: 11721458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between implantable cardioverter-defibrillators and class III agents.
    Movsowitz C; Marchlinski FE
    Am J Cardiol; 1998 Aug; 82(4A):41I-48I. PubMed ID: 9737653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between drugs and devices: experimental and clinical studies.
    Manz M; Jung W; Lüderitz B
    Am Heart J; 1994 Apr; 127(4 Pt 2):978-84. PubMed ID: 8160602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
    Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
    Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of drugs on defibrillation capacity.
    Dopp AL; Miller JM; Tisdale JE
    Drugs; 2008; 68(5):607-30. PubMed ID: 18370441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.
    Bunch TJ; Anderson JL
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):89-100. PubMed ID: 24288157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
    Singh S; Murawski MM
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):175-80. PubMed ID: 17875944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place?
    McCollam PL; Nappi JM
    Ann Pharmacother; 1993 Jun; 27(6):736-41. PubMed ID: 8329797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a combination of class III and class Ic antiarrhythmic agents in patients with electrical storm.
    Fuchs T; Groysman R; Meilichov I
    Pharmacotherapy; 2008 Jan; 28(1):14-9. PubMed ID: 18154469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
    Ho AT; Pai SM; Timothy P; Pai RG
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?].
    Tanner H; Hindricks G; Kottkamp H
    Herz; 2005 Nov; 30(7):613-8. PubMed ID: 16333587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.
    Droogan C; Patel C; Yan GX; Kowey PR
    Heart Fail Clin; 2011 Apr; 7(2):195-205, viii. PubMed ID: 21439498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute management of ventricular arrhythmias: role of antiarrhythmic agents.
    Singh BN
    Pharmacotherapy; 1997; 17(2 Pt 2):56S-64S; discussion 89S-91S. PubMed ID: 9085341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
    Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
    Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors of defibrillation threshold in patients with implantable cardioverter-defibrillators.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Swiatecka G
    Kardiol Pol; 2005 Apr; 62(4):317-28; discussion 329-31. PubMed ID: 15928737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.